IL155116A0 - Pharmaceutical compositions containing as inhibitor of dipeptidyl peptidase iv and of similar enzymes - Google Patents

Pharmaceutical compositions containing as inhibitor of dipeptidyl peptidase iv and of similar enzymes

Info

Publication number: IL155116A0
Authority: IL; Israel
Prior art keywords: npy; activity; inhibitor; reduction; pharmaceutical compositions
Prior art date: 2000-10-27

Application number

IL15511601A

Other languages

English (en)

Original Assignee

Probiodrug Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-27

Filing date

2001-10-29

Publication date

2003-10-31

2001-10-29 Application filed by Probiodrug Ag filed Critical Probiodrug Ag

2003-10-31 Publication of IL155116A0 publication Critical patent/IL155116A0/xx

Links

102000004190 Enzymes Human genes 0.000 title abstract 2
108090000790 Enzymes Proteins 0.000 title abstract 2
239000003112 inhibitor Substances 0.000 title abstract 2
102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 title 1
101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
101710151321 Melanostatin Proteins 0.000 abstract 3
102400000064 Neuropeptide Y Human genes 0.000 abstract 3
230000000694 effects Effects 0.000 abstract 3
URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 abstract 3
208000019901 Anxiety disease Diseases 0.000 abstract 1
102100027936 Attractin Human genes 0.000 abstract 1
101710134735 Attractin Proteins 0.000 abstract 1
208000000094 Chronic Pain Diseases 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
241001465754 Metazoa Species 0.000 abstract 1
208000002193 Pain Diseases 0.000 abstract 1
102000001708 Protein Isoforms Human genes 0.000 abstract 1
108010029485 Protein Isoforms Proteins 0.000 abstract 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 1
208000005392 Spasm Diseases 0.000 abstract 1
230000000202 analgesic effect Effects 0.000 abstract 1
230000001430 anti-depressive effect Effects 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
239000002249 anxiolytic agent Substances 0.000 abstract 1
230000000949 anxiolytic effect Effects 0.000 abstract 1
210000004556 brain Anatomy 0.000 abstract 1
230000015556 catabolic process Effects 0.000 abstract 1
230000001364 causal effect Effects 0.000 abstract 1
238000006731 degradation reaction Methods 0.000 abstract 1
230000003001 depressive effect Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
206010015037 epilepsy Diseases 0.000 abstract 1
206010022437 insomnia Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000001537 neural effect Effects 0.000 abstract 1
230000000926 neurological effect Effects 0.000 abstract 1
108010043412 neuropeptide Y-Y1 receptor Proteins 0.000 abstract 1
BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 abstract 1
230000002035 prolonged effect Effects 0.000 abstract 1
201000000980 schizophrenia Diseases 0.000 abstract 1
239000000758 substrate Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Rheumatology (AREA)
Anesthesiology (AREA)
Physical Education & Sports Medicine (AREA)
Nutrition Science (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

IL15511601A 2000-10-27 2001-10-29 Pharmaceutical compositions containing as inhibitor of dipeptidyl peptidase iv and of similar enzymes IL155116A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US24403600P	2000-10-27	2000-10-27
PCT/EP2001/012479 WO2002034243A2 (en)	2000-10-27	2001-10-29	Method for the treatment of neurological and neuropsychological disorders

Publications (1)

Publication Number	Publication Date
IL155116A0 true IL155116A0 (en)	2003-10-31

Family

ID=22921137

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
IL15511601A IL155116A0 (en)	2000-10-27	2001-10-29	Pharmaceutical compositions containing as inhibitor of dipeptidyl peptidase iv and of similar enzymes
IL15515701A IL155157A0 (en)	2000-10-27	2001-10-29	Pharmaceutical compositions containing an attractin inhibitor
IL155116A IL155116A (en)	2000-10-27	2003-03-27	Pharmaceutical compositions containing an inhibitor of dipeptidyl peptidase iv and of similar enzymes
IL196994A IL196994A0 (en)	2000-10-27	2009-02-11	Pharmaceutical compositions containing an inhibitor of dipeptidyl peptidase iv and of similar enzymes for use in the treatment of depression and schizophrenia

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
IL15515701A IL155157A0 (en)	2000-10-27	2001-10-29	Pharmaceutical compositions containing an attractin inhibitor
IL155116A IL155116A (en)	2000-10-27	2003-03-27	Pharmaceutical compositions containing an inhibitor of dipeptidyl peptidase iv and of similar enzymes
IL196994A IL196994A0 (en)	2000-10-27	2009-02-11	Pharmaceutical compositions containing an inhibitor of dipeptidyl peptidase iv and of similar enzymes for use in the treatment of depression and schizophrenia

Country Status (19)

Country	Link
US (1)	US20040043919A1 (xx)
EP (2)	EP1328271B1 (xx)
JP (2)	JP2004512300A (xx)
KR (2)	KR20030096227A (xx)
CN (3)	CN101143217A (xx)
AT (1)	ATE399008T1 (xx)
AU (3)	AU2177302A (xx)
BR (2)	BR0114921A (xx)
CA (3)	CA2424475A1 (xx)
CY (1)	CY1108336T1 (xx)
DE (1)	DE60134563D1 (xx)
DK (1)	DK1328271T3 (xx)
ES (1)	ES2309108T3 (xx)
IL (4)	IL155116A0 (xx)
NO (2)	NO20031849L (xx)
PT (1)	PT1328271E (xx)
RU (3)	RU2003115614A (xx)
WO (2)	WO2002034243A2 (xx)
ZA (2)	ZA200302394B (xx)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2304206A1 (en) *	1997-09-29	1999-04-08	Point Therapeutics, Inc.	Stimulation of hematopoietic cells in vitro
US6979697B1 (en) *	1998-08-21	2005-12-27	Point Therapeutics, Inc.	Regulation of substrate activity
US6890904B1 (en) *	1999-05-25	2005-05-10	Point Therapeutics, Inc.	Anti-tumor agents
AU2177302A (en) *	2000-10-27	2002-05-06	Probiodrug Ag	Method for the treatment of neurological and neuropsychological disorders
US7132104B1 (en)	2000-10-27	2006-11-07	Probiodrug Ag	Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders
HUP0400321A2 (hu)	2001-06-27	2004-08-30	Smithkline Beecham Corp.	Fluorpirrolidin-származékok mint dipeptidil-dipeptidáz inhibitorok és ezeket tartalmazó gyógyszerkészítmények
AU2003214534B2 (en)	2002-04-08	2006-08-31	Torrent Pharmaceuticals Ltd.	Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
WO2004004658A2 (en) *	2002-07-09	2004-01-15	Point Therapeutics, Inc.	Methods and compositions relating to isoleucine boroproline compounds
US7550590B2 (en)	2003-03-25	2009-06-23	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
DK1620082T3 (da)	2003-05-05	2010-08-16	Probiodrug Ag	Medicinsk anvendelse af inhibitorer af glutaminyl- og glutamatcyclaser til behandling af Alzheimers sygdom og Downs syndrom
NZ568459A (en)	2003-05-05	2009-06-26	Probiodrug Ag	Use of effectors of glutaminyl and glutamate cyclases
EP1625122A1 (en)	2003-05-14	2006-02-15	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
ZA200602051B (en)	2003-08-13	2007-10-31	Takeda Pharmaceutical	4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
US7678909B1 (en)	2003-08-13	2010-03-16	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7169926B1 (en)	2003-08-13	2007-01-30	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
EP1699777B1 (en)	2003-09-08	2012-12-12	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
NZ546322A (en)	2003-10-15	2008-11-28	Probiodrug Ag	Use of effectors of glutaminyl and glutamate cyclases
US7732446B1 (en)	2004-03-11	2010-06-08	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
BRPI0418639B8 (pt)	2004-03-15	2021-05-25	Takeda Pharmaceutical	compostos inibidores de dipeptidil peptidase, assim como composição farmacêutica contendo os mesmos
US7687638B2 (en)	2004-06-04	2010-03-30	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
WO2006019965A2 (en)	2004-07-16	2006-02-23	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
US20060063719A1 (en) *	2004-09-21	2006-03-23	Point Therapeutics, Inc.	Methods for treating diabetes
WO2006068978A2 (en)	2004-12-21	2006-06-29	Takeda Pharmaceutial Company Limited	Dipeptidyl peptidase inhibitors
ZA200802857B (en)	2005-09-14	2009-09-30	Takeda Pharmaceutical	Dipeptidyl peptidase inhibitors for treating diabetes
CN101360723A (zh)	2005-09-16	2009-02-04	武田药品工业株式会社	制备嘧啶二酮衍生物的方法
WO2007112347A1 (en)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
EA200802054A1 (ru)	2006-04-12	2009-04-28	Пробиодруг Аг	Ингибиторы фермента
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
RU2350331C1 (ru) *	2007-07-10	2009-03-27	Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева"	Способ лечения невроза навязчивых состояний
RU2350330C1 (ru) *	2007-11-13	2009-03-27	Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева"	Способ лечения истерического невроза
JO2870B1 (en)	2008-11-13	2015-03-15	ميرك شارب اند دوهم كورب	Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
JP5734981B2 (ja)	2009-09-02	2015-06-17	メルク・シャープ・エンド・ドーム・コーポレイション	糖尿病の治療又は予防のためのジペプチジルペプチダーゼｉｖ阻害剤としてのアミノテトラヒドロピラン
WO2011079778A1 (en)	2009-12-30	2011-07-07	China Shanghai Fochon Pharmaceutical Co Ltd	3-(3-aminopiperidin-1-yl)-5-oxo-1,2,4-triazine derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
EP2538783B1 (en)	2010-02-22	2016-06-01	Merck Sharp & Dohme Corp.	Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
US8980929B2 (en)	2010-05-21	2015-03-17	Merck Sharp & Dohme Corp.	Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
WO2013122920A1 (en)	2012-02-17	2013-08-22	Merck Sharp & Dohme Corp.	Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US9668969B1 (en)	2012-02-22	2017-06-06	Arturo Solis Herrera	Methods of using QIAPINE
WO2014018350A1 (en)	2012-07-23	2014-01-30	Merck Sharp & Dohme Corp.	Treating diabetes with dipeptidyl peptidase-iv inhibitors
CN107213465A (zh) *	2017-06-23	2017-09-29	武汉大学	二肽基肽酶iv抑制剂在制备防治癫痫的药物中的应用
CN119380997B (zh) *	2024-12-27	2025-03-21	内蒙古医科大学附属医院(内蒙古自治区心血管研究所)	一种神经内科康复程度评价方法及系统

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US25023A (en) *		1859-08-09		Improved device for making electro-magnetic currents, constant or intermittent
US2961377A (en) *	1957-08-05	1960-11-22	Us Vitamin Pharm Corp	Oral anti-diabetic compositions and methods
US3174901A (en) *	1963-01-31	1965-03-23	Jan Marcel Didier Aron Samuel	Process for the oral treatment of diabetes
US3879541A (en) *	1970-03-03	1975-04-22	Bayer Ag	Antihyperglycemic methods and compositions
US3960949A (en) *	1971-04-02	1976-06-01	Schering Aktiengesellschaft	1,2-Biguanides
CH602612A5 (xx) *	1974-10-11	1978-07-31	Hoffmann La Roche
US4935493A (en) *	1987-10-06	1990-06-19	E. I. Du Pont De Nemours And Company	Protease inhibitors
US5433955A (en) *	1989-01-23	1995-07-18	Akzo N.V.	Site specific in vivo activation of therapeutic drugs
DE4039415A1 (de) *	1990-02-03	1991-08-08	Boehringer Mannheim Gmbh	Verfahren zur herstellung rekombinanter proteine ohne n-terminalen methioninrest
US5462928A (en) *	1990-04-14	1995-10-31	New England Medical Center Hospitals, Inc.	Inhibitors of dipeptidyl-aminopeptidase type IV
IL106998A0 (en) *	1992-09-17	1993-12-28	Univ Florida	Brain-enhanced delivery of neuroactive peptides by sequential metabolism
IL111785A0 (en) *	1993-12-03	1995-01-24	Ferring Bv	Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en) *	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
US5543396A (en) *	1994-04-28	1996-08-06	Georgia Tech Research Corp.	Proline phosphonate derivatives
US5512549A (en) *	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5614379A (en) *	1995-04-26	1997-03-25	Eli Lilly And Company	Process for preparing anti-obesity protein
DE122010000020I1 (de) *	1996-04-25	2010-07-08	Prosidion Ltd	Verfahren zur Senkung des Blutglukosespiegels in Säugern
US6006753A (en) *	1996-08-30	1999-12-28	Eli Lilly And Company	Use of GLP-1 or analogs to abolish catabolic changes after surgery
US5827898A (en) *	1996-10-07	1998-10-27	Shaman Pharmaceuticals, Inc.	Use of bisphenolic compounds to treat type II diabetes
US6011155A (en) *	1996-11-07	2000-01-04	Novartis Ag	N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
EP1052994A2 (en) *	1998-02-02	2000-11-22	Trustees Of Tufts College	Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
WO1999046272A1 (en) *	1998-03-09	1999-09-16	Fondatech Benelux N.V.	Serine peptidase modulators
DE19823831A1 (de) *	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19834591A1 (de) *	1998-07-31	2000-02-03	Probiodrug Ges Fuer Arzneim	Verfahren zur Steigerung des Blutglukosespiegels in Säugern
AU3960400A (en) *	1999-03-05	2000-09-28	Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A.	Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
US6107317A (en) *	1999-06-24	2000-08-22	Novartis Ag	N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6110949A (en) *	1999-06-24	2000-08-29	Novartis Ag	N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6172081B1 (en) *	1999-06-24	2001-01-09	Novartis Ag	Tetrahydroisoquinoline 3-carboxamide derivatives
IL151368A0 (en) *	2000-03-31	2003-04-10	Probiodrug Ag	Use of a dipeptidyl peptidase iv enzyme activity effector for the production of pharmaceutical compositions
AU2177302A (en) *	2000-10-27	2002-05-06	Probiodrug Ag	Method for the treatment of neurological and neuropsychological disorders

2001
- 2001-10-29 AU AU2177302A patent/AU2177302A/xx active Pending
- 2001-10-29 ZA ZA200302394A patent/ZA200302394B/en unknown
- 2001-10-29 EP EP01988583A patent/EP1328271B1/en not_active Expired - Lifetime
- 2001-10-29 WO PCT/EP2001/012479 patent/WO2002034243A2/en not_active Ceased
- 2001-10-29 CA CA002424475A patent/CA2424475A1/en not_active Abandoned
- 2001-10-29 ES ES01988583T patent/ES2309108T3/es not_active Expired - Lifetime
- 2001-10-29 PT PT01988583T patent/PT1328271E/pt unknown
- 2001-10-29 AT AT01988583T patent/ATE399008T1/de active
- 2001-10-29 KR KR10-2003-7005769A patent/KR20030096227A/ko not_active Ceased
- 2001-10-29 AU AU2002227898A patent/AU2002227898A1/en not_active Abandoned
- 2001-10-29 AU AU2002221773A patent/AU2002221773B2/en not_active Ceased
- 2001-10-29 JP JP2002537297A patent/JP2004512300A/ja active Pending
- 2001-10-29 CA CA002689012A patent/CA2689012A1/en not_active Abandoned
- 2001-10-29 CN CNA2006101219115A patent/CN101143217A/zh active Pending
- 2001-10-29 CA CA2422889A patent/CA2422889C/en not_active Expired - Fee Related
- 2001-10-29 JP JP2002537296A patent/JP2004512299A/ja not_active Withdrawn
- 2001-10-29 KR KR10-2003-7005718A patent/KR20040025875A/ko not_active Withdrawn
- 2001-10-29 WO PCT/EP2001/012478 patent/WO2002034242A2/en not_active Ceased
- 2001-10-29 DE DE60134563T patent/DE60134563D1/de not_active Expired - Lifetime
- 2001-10-29 RU RU2003115614/14A patent/RU2003115614A/ru not_active Application Discontinuation
- 2001-10-29 EP EP01988582A patent/EP1328270A2/en not_active Withdrawn
- 2001-10-29 RU RU2003115622/14A patent/RU2286149C2/ru not_active IP Right Cessation
- 2001-10-29 BR BR0114921-0A patent/BR0114921A/pt not_active Application Discontinuation
- 2001-10-29 ZA ZA200302590A patent/ZA200302590B/en unknown
- 2001-10-29 US US10/415,263 patent/US20040043919A1/en not_active Abandoned
- 2001-10-29 CN CNA01817857XA patent/CN1471392A/zh active Pending
- 2001-10-29 BR BR0114924-5A patent/BR0114924A/pt not_active IP Right Cessation
- 2001-10-29 CN CNB018180671A patent/CN1278683C/zh not_active Expired - Fee Related
- 2001-10-29 IL IL15511601A patent/IL155116A0/xx unknown
- 2001-10-29 DK DK01988583T patent/DK1328271T3/da active
- 2001-10-29 IL IL15515701A patent/IL155157A0/xx unknown
2003
- 2003-03-27 IL IL155116A patent/IL155116A/en not_active IP Right Cessation
- 2003-04-24 NO NO20031849A patent/NO20031849L/no unknown
- 2003-04-25 NO NO20031867A patent/NO20031867L/no not_active Application Discontinuation
2006
- 2006-06-20 RU RU2006122179/15A patent/RU2416406C2/ru not_active IP Right Cessation
2008
- 2008-09-11 CY CY20081100982T patent/CY1108336T1/el unknown
2009
- 2009-02-11 IL IL196994A patent/IL196994A0/en unknown

Also Published As

Publication number	Publication date
CN1471392A (zh)	2004-01-28
NO20031849D0 (no)	2003-04-24
DK1328271T3 (da)	2008-10-13
EP1328270A2 (en)	2003-07-23
DE60134563D1 (de)	2008-08-07
KR20030096227A (ko)	2003-12-24
CA2424475A1 (en)	2002-05-02
WO2002034242A3 (en)	2003-01-30
NO20031867D0 (no)	2003-04-25
IL155116A (en)	2009-09-01
RU2416406C2 (ru)	2011-04-20
HK1062643A1 (en)	2004-11-19
US20040043919A1 (en)	2004-03-04
WO2002034243A2 (en)	2002-05-02
AU2177302A (en)	2002-05-06
KR20040025875A (ko)	2004-03-26
WO2002034243A3 (en)	2003-01-30
ZA200302394B (en)	2004-03-29
PT1328271E (pt)	2008-08-26
CY1108336T1 (el)	2014-02-12
CA2422889A1 (en)	2002-05-02
BR0114921A (pt)	2003-12-23
RU2006122179A (ru)	2007-12-27
ES2309108T3 (es)	2008-12-16
ZA200302590B (en)	2004-04-02
CN1278683C (zh)	2006-10-11
NO20031867L (no)	2003-06-19
AU2002221773B2 (en)	2005-12-22
EP1328271B1 (en)	2008-06-25
JP2004512299A (ja)	2004-04-22
EP1328271A2 (en)	2003-07-23
CA2689012A1 (en)	2002-05-02
WO2002034242A2 (en)	2002-05-02
CA2422889C (en)	2010-01-26
ATE399008T1 (de)	2008-07-15
CN1471393A (zh)	2004-01-28
IL196994A0 (en)	2011-07-31
BR0114924A (pt)	2003-12-23
AU2002227898A1 (en)	2002-05-06
CN101143217A (zh)	2008-03-19
RU2003115614A (ru)	2004-10-27
RU2286149C2 (ru)	2006-10-27
NO20031849L (no)	2003-06-23
IL155157A0 (en)	2003-10-31
JP2004512300A (ja)	2004-04-22

Publication	Publication Date	Title
IL196994A0 (en)	2011-07-31	Pharmaceutical compositions containing an inhibitor of dipeptidyl peptidase iv and of similar enzymes for use in the treatment of depression and schizophrenia
MY127961A (en)	2007-01-31	Beta-amino heterocyclic dipetidyl peptidase inhibitors for the treament or prevention of diabetes
ATE390416T1 (de)	2008-04-15	Heterozyklische beta-aminoverbindungen als inhibitoren des dipeptidylpeptidase zur behandlung bzw. prevention von diabetes
MXPA04005790A (es)	2004-09-13	Compuestos y usos de los mismos para reducir la actividad de la lipasa sensible a la hormona.
TW200635912A (en)	2006-10-16	Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase
WO2002038171A3 (en)	2003-04-24	METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF α-L-IDURONIDASE
MX337511B (es)	2016-03-09	Medicamentos y metodos para tratar cefaleas.
ATE244717T1 (de)	2003-07-15	Inhibitoren des impdh-enzyms
RU2003115622A (ru)	2004-10-27	Способ для лечения неврологических и нейропсихологических нарушений
ATE350374T1 (de)	2007-01-15	Phenylalaninderivate als hemmer der dipeptidyl peptidase zur behandlung oder prävention von diabetes
BR0009043A (pt)	2002-01-08	Composto, composição farmacêutica, e, método de tratar uma doença em um animal em que a atividade da cisteìna protease contribui para a patologia e/ou sintomatologia da doença
MXPA05013224A (es)	2006-03-09	Piridinilcarbamatos como inhibidores de lipasa sensible a hormonas.
TW200505416A (en)	2005-02-16	Bi-aryl compound having immunosuppressive activity
ATE356634T1 (de)	2007-04-15	Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
WO2004035086A3 (en)	2004-07-22	Method for treatment of demyelinating central nervous system disease using gm-csf
DE69329550D1 (de)	2000-11-16	2,5-diaryl tetrahydro-thiopene, -furane und analoge zur behandlung von entzündungs-und immunkrankheiten
ATE409469T1 (de)	2008-10-15	Verwendung von 2,2,3,3, tetramethylcyclopropane carbonsäure derivaten zur behandlung von psychiatrischen störungen
WO1997048795A3 (en)	1998-04-30	Compositions and methods for treating specific gene expression-related diseases and disorders in humans